(NASDAQ: GERN) Geron's forecast annual revenue growth rate of 36.53% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.73%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.59%.
Geron's revenue in 2026 is $204,559,000.On average, 7 Wall Street analysts forecast GERN's revenue for 2026 to be $154,232,166,565, with the lowest GERN revenue forecast at $146,766,625,552, and the highest GERN revenue forecast at $160,753,271,666. On average, 7 Wall Street analysts forecast GERN's revenue for 2027 to be $223,497,224,789, with the lowest GERN revenue forecast at $198,479,310,242, and the highest GERN revenue forecast at $278,820,610,038.
In 2028, GERN is forecast to generate $344,166,580,467 in revenue, with the lowest revenue forecast at $272,627,166,375 and the highest revenue forecast at $504,309,502,395.